0001193125-26-098491
SEC filingDesign Therapeutics, Inc. reported a net loss of $69.8 million for fiscal year 2025, driven by a loss from operations of $79.5 million. The company generated no revenue during the period. Operating expenses totaled $79.5 million, consisting primarily of research and development costs of $59.1 million and general and administrative expenses of $20.3 million. Interest income of $9.7 million partially offset the operating loss. The company ended the year with $226.2 million in total assets, including $223.8 million in current assets comprised of $16.9 million in cash and cash equivalents and $203.0 million in investment securities. Total liabilities were $13.7 million, resulting in stockholders' equity of $212.5 million. Net cash used in operating activities was $54.4 million, while investing activities provided $22.9 million and financing activities provided $25.7 million, leading to a net decrease in cash and cash equivalents of $5.7 million for the year.
Design Therapeutics, Inc. reported a net loss of $69.8 million for fiscal year 2025, representing the company's financial performance for the period ending December 31, 2025. The company generated no revenue during the fiscal year. The loss from operations was $79.5 million, which was partially offset by interest income of $9.7 million. Operating expenses totaled $79.5 million, consisting of research and development expenses of $59.1 million and general and administrative expenses of $20.3 million. Basic and diluted net loss per share were both $1.00, calculated using weighted-average shares of common stock outstanding of 57.3 million for both basic and diluted calculations.
The company reported no revenue for fiscal year 2025. The XBRL data shows no revenue figures, and the document content confirms this with revenue fields marked as N/A. The company's financial statements indicate it is in the development stage with no commercial products generating revenue. Grant revenue is also reported as N/A, indicating no grant income during the period. The absence of revenue is consistent with the company's status as a clinical-stage biotechnology company focused on research and development activities rather than commercial operations.
With no revenue generated during fiscal year 2025, gross margin and operating margin calculations are not applicable. The company reported a loss from operations of $79.5 million, representing the total operating expenses for the period. Research and development expenses of $59.1 million constituted approximately 74% of total operating expenses, while general and administrative expenses of $20.3 million represented approximately 26% of operating expenses. The company's cost structure reflects its focus on research and development activities as a clinical-stage biotechnology company without commercial operations.
Net cash used in operating activities was $54.4 million for fiscal year 2025. Cash flows from investing activities provided $22.9 million, primarily from net proceeds of $23.1 million from investment security activities ($314.9 million from maturities minus $291.8 million in purchases). Cash flows from financing activities provided $25.7 million, mainly from $24.8 million in net proceeds from common stock issuance. The company ended the period with $226.2 million in total assets, including $223.8 million in current assets. Total liabilities were $13.7 million, resulting in stockholders' equity of $212.5 million. Cash and cash equivalents decreased by $5.7 million during the year to $21.2 million at period end.
The filing does not provide specific management guidance, strategic priorities, or forward-looking statements in the provided content. The company's financial statements reflect its status as a clinical-stage biotechnology company with significant research and development expenses and no commercial revenue. The balance sheet shows substantial investment securities of $203.0 million and stockholders' equity of $212.5 million, indicating available resources to fund operations. No specific risk factors or strategic initiatives are detailed in the provided financial data sections.